Drug Profile


Alternative Names: MK-8931; SCH-900931

Latest Information Update: 25 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antidementias; Fluorobenzenes; Pyridines; Small molecules; Thiadiazines
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 25 Nov 2016 Efficacy and adverse events data from a phase I trial in Alzheimer's disease released by Merck and Co.
  • 01 Oct 2016 Merck Sharp & Dohme initiates a two-part phase I pharmacokinetics trial in USA (PO, Tablet) (NCT02910739)
  • 20 Sep 2016 Merck Sharp & Dohme plans a two-part phase pharmacokinetics I trial in USA (PO, Tablet) (NCT02910739)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top